Results 91 to 100 of about 44,923 (207)

Transpapillary Placement of a Multihole Covered Metal Stent Using a 5.9‐Fr Delivery System Through a Forward‐viewing Endoscope in Malignant Biliary Obstruction With Type I Duodenal Stenosis

DEN Open, Volume 7, Issue 1, April 2027.
ABSTRACT Concurrent malignant biliary obstruction (MBO) and type I duodenal stenosis represent a technically demanding scenario, as luminal narrowing frequently precludes passage of a standard side‐viewing duodenoscope and limits conventional transpapillary drainage.
Kengo Matsumoto, Daisuke Kondo, Satoru Okabe, Naoto Osugi, Akira Doi, Masashi Yamamoto, Shiro Hayashi, Koji Fukui, Tsutomu Nishida   +8 more
wiley   +1 more source

Pancreatic Cancer—Advances in the Last 50 Years

World Journal of Surgery, EarlyView.
S. George Barreto, Anirban Maitra, Eileen M. O'Reilly, Dushyant Sahani, Richard Zheng, Charles J. Yeo   +5 more
wiley   +1 more source

Plasma PlGF as a Potential Biomarker in Ramucirumab‐Based Second‐Line Therapy for Advanced Gastroesophageal Adenocarcinoma: Exploratory Biomarker Analysis from the Phase II Part of the RAMIRIS Trial

International Journal of Cancer, Volume 159, Issue 7, Page 1817-1828, 1 October 2026.
Antiangiogenic treatment with ramucirumab is a standard second‐line option in advanced gastric and gastroesophageal junction adenocarcinoma. However, reliable biomarkers are currently lacking. This exploratory biomarker analysis of the RAMIRIS trial suggests that elevated baseline and early on‐treatment levels of the pro‐angiogenic placental growth ...
Jurek Hille, Sylvie Lorenzen, Claudia Pauligk, Victoria Gensch, Peter Thuss‐Patience, Eray Goekkurt, Thomas Ettrich, Florian Lordick, Carsten Bokemeyer, Christian Müller, Peter Reichardt, Martin Sökler, Daniel Pink, Stefan Probst, Thorsten O. Goetze, Salah E. Al‐Batran, Sonja Loges, Melanie Janning   +17 more
wiley   +1 more source

Population pharmacokinetics of intraperitoneal irinotecan and SN‐38 in patients with peritoneal metastases from colorectal origin

CPT: Pharmacometrics & Systems Pharmacology
Peritoneal metastases (PM) are common in patients with colorectal cancer. Patients with PM have a poor prognosis, and for those who are not eligible for cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC ...
Pascale C. S. Rietveld, Sebastiaan D. T. Sassen, Niels A. D. Guchelaar, Ruben A. G. vanEerden, Nadine L. deBoer, Teun B. M. van denHeuvel, Jacobus W. A. Burger, Ron H. J. Mathijssen, Birgit C. P. Koch, Stijn L. W. Koolen   +9 more
doaj   +1 more source

Transcriptome‐Based Classification of Resected Pancreatic Ductal Adenocarcinoma Enhances Prognostic Modelling Accuracy of Overall Survival Following Adjuvant Treatment

International Journal of Cancer, Volume 159, Issue 5, Page 1322-1336, 1 September 2026.
Outcomes after resection of pancreatic ductal adenocarcinoma remain highly variable, and existing prognostic models lack sufficient accuracy. Here, the authors aimed to improve survival prediction by integrating transcriptome‐based subtyping into a validated clinical model and applying it to a multicenter real‐world cohort of fresh‐frozen resection ...
Marjolein F. Lansbergen, Vincent R. Lanting, Paul Manoukian, Marc G. Besselink, Geert Kazemier, Ignace H. J. T. de Hingh, Mike S. L. Liem, Casper H. J. van Eijck, Erwin van der Harst, Vincent E. de Meijer, Ronald M. van Dam, Martijn W. J. Stommel, Jan Koster, Michael W. T. Tanck, Arantza Fariña Sarasqueta, Joanne Verheij, Frederike Dijk, Johanna W. Wilmink, Maarten F. Bijlsma, Hanneke W. M. van Laarhoven, for the Dutch Pancreatic Cancer Group   +20 more
wiley   +1 more source

Ramucirumab plus FOLFIRI or irinotecan as second-line treatment for patients with gastroesophageal adenocarcinoma: a review and meta-analysis of an emerging option

Frontiers in Oncology
IntroductionThe aim of this study was to provide a review of the clinical evidence for use of ramucirumab (RAM) plus folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan (FOLFIRI) or irinotecan as second-line treatment in gastroesophageal ...
Haeseong Park, Samuel J. Klempner, Joseph Chao, Zev A. Wainberg, Mariusz Lukanowski, Suresh Chenji, Shannon Bourke, Anindya Chatterjee, Sylvie Lorenzen   +8 more
doaj   +1 more source

Nanomaterial‐Mediated Radiotherapy–Immunotherapy Combinations: Breaking Immunosuppression and Revolutionizing Cancer Treatment

MedComm – Biomaterials and Applications, Volume 5, Issue 3, September 2026.
Nanomaterials integrate radiotherapy and immunotherapy by enhancing radiosensitivity, remodeling the immunosuppressive tumor microenvironment, and promoting systemic antitumor immunity. This review summarizes the latest strategies of nanomaterial‐mediated combinations (RT, immunotherapy, IRT) and highlights future directions for overcoming clinical ...
Peijie Li, Xiangqin Wang, Sisi He, Hu Ma
wiley   +1 more source

Dual‐Drug‐Loaded Liposomes: Design Strategies, Mechanistic Insights, and Therapeutic Applications in Cancer

MedComm – Biomaterials and Applications, Volume 5, Issue 3, September 2026.
Dual‐drug‐loaded liposomes enable the simultaneous delivery of hydrophilic and hydrophobic therapeutics to tumors, enhancing anticancer efficacy and overcoming multidrug resistance. Through rational formulation design and surface functionalization, these systems improve tumor targeting, modulate efflux mechanisms and EMT, and achieve synergistic ...
Neelam Sinha, Rohan Chand Sahu, Rohit Patil, Dinesh Kumar, Ashish Kumar Agrawal   +4 more
wiley   +1 more source

Nanoparticle‐Mediated Therapy for Glioma: Advances and Prospects

MedComm – Oncology, Volume 5, Issue 3, September 2026.
Various nanocarriers, including liposomes, dendrimers, exosomes and gold nanoparticles, are designed to penetrate the blood‐brain barrier and deliver chemotherapy, radiotherapy, immunotherapy, gene therapy, phototherapy, magnetic hyperthermia and sonodynamic therapy for glioma.
Wenqian Jiang, Jing Fei, Rangrang Fan, Haifeng Chen, Liangxue Zhou, Gang Guo   +5 more
wiley   +1 more source

Oxysterols in Cancer: From Biosynthesis and Pathophysiology to Targeted Therapeutics

MedComm – Oncology, Volume 5, Issue 3, September 2026.
Mechanisms by which oxysterol targeting may enhance immunotherapy efficacy. This figure illustrates potential metabolic interventions that may improve antitumor immunity by modulating oxysterol related pathways. CH25H modulation may reduce 25‐HC accumulation, promote the conversion of cold tumors into hot tumors, and increase T cell infiltration and PD‐
Haili Shang, Yongsheng Li
wiley   +1 more source